Topline
Danish pharmaceutical giant Novo Nordisk reported the most robust quarterly profits and sales in its history Thursday, as Europe’s largest public company rides the surge in popularity of its weight loss and diabetes drugs to blockbuster results.
Key Facts
Novo Nordisk primarily produces diabetes medications, including the injectable GLP-1 semaglutide drugs Wegovy and Ozempic, which have become particularly popular in the U.S. recently for their efficacy in promoting weight loss.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased